文献速递膀胱癌与上尿路尿路上皮癌

ERAS用于日间TURBT:EMBRACE随机对照试验结果

Results From the ERAS for Ambulatory TURBT: Enhancing Bladder Cancer Care (EMBRACE) Randomized Controlled Trial.
PubMed 文献 · J Urol · 2026-02-09

主要终点QoR-15评分在ERAS组较对照组高12分(137 vs 125,P < .001),UTI-SIQ-8、疼痛及尿失禁率均显著改善。结论认为ERAS可显著提高日间TURBT患者的恢复质量。

要点

  • ERAS组QoR-15评分较对照组高12分(137 vs 125,P < .001)。
  • ERAS组UTI-SIQ-8评分更低(5.8 vs 12,P < .001)。
  • ERAS组尿失禁率14% vs 41%(P = .02)。

核心结论

  • ERAS用于日间TURBT可显著改善膀胱癌患者的恢复质量。

主要发现

  • ERAS组QoR-15评分在手术当日和术后第1天较对照组高12分(137 vs 125,P < .001)。
  • ERAS组UTI-SIQ-8评分低于对照组(5.8 vs 12,P < .001)。
  • ERAS组尿道疼痛(2.4 vs 4,P < .01)、阴茎/外阴疼痛(1.3 vs 2.7,P < .01)和排尿困难(2.6 vs 4.4,P < .001)均低于对照组。
  • ERAS组尿失禁率低于对照组(14% vs 41%,P = .02)。

临床怎么用

  • 在日间TURBT中实施包含术前患者教育及术中术后麻醉/手术干预的ERAS方案,可改善恢复质量并减少术后泌尿系统症状和尿失禁。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Transurethral resection of a bladder tumor (TURBT) contributes to morbidity of patients with bladder cancer. This trial evaluates the impact of an enhanced recovery after surgery (ERAS) protocol on quality of recovery from ambulatory TURBT. MATERIALS AND METHODS: In a prospective, single institution randomized controlled trial, patients undergoing ambulatory TURBT were randomized to ERAS (including preoperative patient education, intraoperative and postoperative anesthesia/surgery interventions) or usual care, January 2024 to May 2024. The primary end point was the mean difference in Quality of Recovery-15 (QoR-15) score (0-150, higher is superior recovery) between groups over day of surgery and postoperative day 1 (POD1). Secondary end points included urinary tract infection-symptom impairment questionnaire (UTI-SIQ-8), pain scores, and incontinence rates on POD1. RESULTS: Patients were randomized in a 1:1 ratio to ERAS (n = 50) or usual care (n = 50). On multivariable analysis, the mean QoR-15 was 12 points higher in ERAS group vs controls for day of surgery and POD1, 137 vs 125, respectively (P < .001). UTI-SIQ-8 was lower in the ERAS group vs control: 5.8 vs 12, P < .001. ERAS patients experienced reduced urethral pain (2.4 vs 4, P < .01), penile/vulvar pain (1.3 vs 2.7, P < .01), dysuria (2.6 vs 4.4, P < .001), and urinary incontinence (14% vs 41%, P = .02) vs controls. CONCLUSIONS: Utilization of ERAS for ambulatory TURBT significantly improves quality of recovery for patients with bladder cancer undergoing this common procedure.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Rezaee ME, Higgins MI, Su ZT, et al. Results From the ERAS for Ambulatory TURBT: Enhancing Bladder Cancer Care (EMBRACE) Randomized Controlled Trial. J Urol. 2026. PMID: 41662513. doi:10.1097/JU.0000000000004983

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。